Supernus Pharmaceuticals (SUPN) Earnings Analysis
Supernus Pharmaceuticals (SUPN) has no confirmed upcoming earnings date. Last quarter (2024-11-04) it beat with EPS 1.06 USD vs 0.39 USD est (+171.8%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E -91.79.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SUPN next report earnings?
No confirmed upcoming earnings date is currently scheduled for SUPN. This page updates as the calendar is published.
SUPN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2024-11-04 | 1.06 USD | 0.39 USD | +171.8% | Beat |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
SUPN valuation and analyst view
| Trailing P/E | -91.79 |
|---|---|
| Trailing EPS | -0.50333 USD |
| Price / book | 2.51 |
| Dividend yield | 0.00% |
| Market cap | 2.74B |
| Analyst consensus | Buy (9 buy / 5 hold / 0 sell) |
| Avg price target | 55 USD |
Related research pages
Frequently asked questions
When is Supernus Pharmaceuticals (SUPN)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for SUPN. This page updates as the calendar is published.
Did SUPN beat earnings last quarter?
In its 2024-11-04 report, SUPN posted EPS of 1.06 USD versus a 0.39 USD estimate — a beat of 171.8%.
What is SUPN's earnings track record?
Over the last 1 reported quarters with consensus data, SUPN beat estimates 1 times (100%).
What is SUPN's current P/E ratio and EPS?
SUPN trades at a trailing P/E of -91.79 on trailing EPS of -0.50333450435741 USD.
What do analysts rate SUPN?
Analyst consensus is "Buy" across 14 ratings (0 strong buy, 9 buy, 5 hold, 0 sell, 0 strong sell). Average 12-month price target: 55 USD.